Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period.

Abstract

Tanezumab, a humanized monoclonal anti-NGF antibody, has demonstrated efficacy and safety profiles in Phase III clinical trials of chronic pain. In a 24-week study in non-human primates, morphological observations of sympathetic ganglia showed decreased ganglia volume, decreased neuronal size, and increased glial cell density compared with controls after 3 tanezumab treatments. Using stereological techniques to quantify glial cells, the present 26-week study found no significant difference after weekly treatments in total cervicothoracic ganglia satellite glial cell number between placebo- or tanezumab-treated cynomolgus monkeys. These findings suggest that tanezumab treatment does not result in a true gliosis in sympathetic ganglia.

• Authors: Mark Evans, Mark Butt, Patrice Belanger, Thomas Cummings, Jessica-Lyn Gremminger, Mark Zorbas
• Journal: Autonomic neuroscience : basic & clinical (Auton Neurosci) Vol. 218 Pg. 51-53 (05 2019) ISSN: 1872-7484 [Electronic] Netherlands
• PMID: 30890348 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019. Published by Elsevier B.V.

Chemical References

• Analgesics
• Antibodies, Monoclonal, Humanized
• tanezumab

Topics

• Analgesics (toxicity)
• Animals
• Antibodies, Monoclonal, Humanized (toxicity)
• Female
• Gliosis (chemically induced)
• Macaca fascicularis
• Male
• Satellite Cells, Perineuronal (drug effects, pathology)
• Stellate Ganglion (drug effects, pathology)